-
- SARS-CoV-2
Dec 19, 2023Viral uptake and pathophysiology of the lung endothelial cells in age-associated severe SARS-CoV-2 infection models -
- flavivirus
Nov 14, 2023Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain -
- SARS-CoV-2
Oct 17, 20232-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses -
- PD-L1
Oct 05, 2023Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours -
- COVID-19
Sep 25, 2023Collaboration with Shionogi for drug discovery – COVID-19 treatment drug “Xocova” effect on Long COVID -
- COVID-19
Jul 07, 2023Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study -
- Mincle
Jun 26, 2023Structural basis for plastic glycolipid recognition of the C-type lectin Mincle -
- CIITA
- MHC class II
- T cells
Jun 08, 2023FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA -
- SARS-CoV-2
May 19, 2023Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants -
- SARS-CoV-2
May 15, 2023Unraveling part of the evolutionary pattern of the SARS-CoV-2 Omicron strain -
- PD-L1
Mar 20, 2023Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves -
- COVID-19
Dec 08, 2022Collaboration with Shionogi for drug discovery – the first domestically produced COVID-19 treatment, Xocova was approved
